Isosorbide mononitrate price in the Philippines
Quick answer
The DOH reference price for isosorbide-5-mononitrate 30 mg modified release capsule is ₱6.05 per capsule (median, June 2024 index); drugstore prices are usually higher. FDA Philippines lists 41 registered isosorbide mononitrate products (checked 2026-11-05): 5 as unbranded generics and 36 under 27 brand names. It is a prescription (Rx) medicine. Ask the pharmacist for the unbranded generic of the same strength; it is on the FDA VAT-exempt list, so no 12% VAT applies.
Government reference price
At the DOH median, 30 capsules cost about ₱181.50, a month at one a day.
DPRI range, DOH DPRI June 2024. What public hospitals pay; drugstore prices are usually higher.
DOH reference prices
Isosorbide mononitrate: DOH reference prices
4 items in the DOH index; the lowest median is ₱6.05 for isosorbide-5-mononitrate 30 mg modified release capsule.
| Item | Lowest (₱) | Median (₱) | Highest (₱) | Type |
|---|---|---|---|---|
| Isosorbide-5-Mononitrate 30 mg Modified Release Capsule | ₱4.90 | ₱6.05 | ₱7.50 | DPRI range |
| Isosorbide-5-Mononitrate 30 mg Modified Release Tablet | ₱2.20 | ₱6.15 | ₱17.00 | DPRI range |
| Isosorbide-5-Mononitrate 60 mg Modified Release Capsule | ₱2.90 | ₱6.90 | ₱12.00 | DPRI range |
| Isosorbide-5-Mononitrate 60 mg Modified Release Tablet | ₱2.90 | ₱6.90 | ₱10.00 | DPRI range |
Source: DOH Drug Price Reference Index, June 2024. Prices per unit (tablet, vial, bottle) in pesos, VAT included unless the medicine is VAT-exempt. Hospitals and other facilities may price up to 6.8% above the index, except MWP items.
Strengths
Isosorbide mononitrate by strength
Isosorbide mononitrate is listed here in 4 strengths; 3 of them (20 mg, 30 mg, 60 mg) have FDA-registered products in the Philippines.
| Strength | DOH median (₱) | FDA products |
|---|---|---|
| Isosorbide mononitrate 20 mg | – | 3 |
| Isosorbide mononitrate 30 mg | ₱6.05 | 19 |
| Isosorbide mononitrate 40 mg | – | not registered |
| Isosorbide mononitrate 60 mg | ₱6.90 | 17 |
Sources: FDA Philippines registry (2026-11-05), DOH DPRI June 2024.
About isosorbide mononitrate
Used for
The US FDA label for isosorbide mononitrate extended-release tablets says they prevent angina, the chest pain that comes from coronary artery disease. They act too slowly to stop an attack that has already started.
This page follows the label for once-a-day extended-release tablets of 30 mg, 60 mg and 120 mg. The 20 mg and 40 mg tablets sold here have their own leaflet with their own doses.
How it works
It is a nitrate, and the main active substance the body makes from isosorbide dinitrate. It relaxes the muscle of blood vessel walls, mostly in the veins. Less blood flows back to the heart, so the heart works less. The heart's own arteries widen too.
How to take it and usual dose
The label gives a starting dose of 30 mg or 60 mg once a day. After several days it can go up to 120 mg once a day. Rarely, 240 mg is needed. Take the tablet in the morning when you get up. Swallow it with half a glass of water or other drink, and do not chew or crush it.
Nitrates lose their effect if their level stays high around the clock. Keeping to the once-a-day morning schedule helps the medicine keep working. Your doctor decides the dose.
Do not use if
- you have had an allergic or unusual reaction to other nitrates or nitrites
Common side effects
Headache is by far the most common side effect. It depends on the dose and often fades as treatment goes on, which is why the label suggests starting low for a few days. Dizziness is the second most common.
Blood pressure can drop sharply, even with small doses, mainly when you stand up. A slow heartbeat and worse chest pain can come with it. Get urgent help if you faint or your chest pain gets worse.
Source: US FDA label (DailyMed), 2026-10-26. A summary of the official label, not medical advice: your doctor or pharmacist knows your case.
Registered products
Registered isosorbide mononitrate products
FDA Philippines lists 41 registrations under 28 brand names (one row is unbranded generics).
| Brand | Strength and form | Class | Manufacturer | Reg. |
|---|---|---|---|---|
| Acunasyn | 20mg Tablet | Rx | Drugmaker's Laboratories Inc. (Philippines) | 1 |
| Angistad | 60mg Sustained Release Capsule | Rx | Valpharma International S.p.A. (Italy) | 1 |
| Angitec | 30 mg Extended-Release Tablet; 60 mg Extended-Release Tablets | Rx | Magbro Healthcare Pvt. Ltd. (IndIa) +1 more | 2 |
| Angitrate | 30 mg Prolonged Release Tablet; 60 mg Prolonged Release Tablet | Rx | Lloyd Laboratories, Inc. (Philippines) | 2 |
| Aysosaph-GE30 | 30 mg Prolonged Release Film Coated Tablet | Rx | Genom Biotech Pvt. Ltd. (India) | 1 |
| Aysosaph-GE60 | 60 mg Prolonged-Release Tablet | Rx | Genom Biotech Pvt. Ltd. (India) | 1 |
| Imdur Durules | 30 mg Film-Coated Tablet; 60 mg Prolonged-Release Tablet | Rx | Laboratorios Alcala Farma, S.L. (Spain) | 2 |
| Ismodin | 30 mg Sustained-Release Tablet; 60 mg Sustained-Release Tablet | Rx | Lloyd Laboratories, Inc. (Philippines) | 2 |
Show 20 more brands
Registered isosorbide mononitrate products, continued
| Brand | Strength and form | Class | Manufacturer | Reg. |
|---|---|---|---|---|
| Isolvide | 30 mg Prolonged Release Tablet; 60 mg Prolonged Release Tablet | Rx | Lloyd Laboratories, Inc. (Philippines) | 2 |
| Isolyte | 30mg Sustained-Release Tablets; 60 mg Sustained-Release Tablet | Rx | Fredun Pharmaceuticals Limited (India) | 2 |
| Isomed 30 | 30 mg Prolonged-Release Tablet | Rx | Flourish Pharma (India) | 1 |
| Isonate | 60 mg Controlled-Release Fim-Coated Tablet | Rx | Shou Chan Industrial Co. Ltd. (Taiwan) | 1 |
| Isored 30 | 30 mg Prolonged Release Film Coated Tablet | Rx | Genom Biotech Pvt. Ltd. (India) | 1 |
| Isored 60 | 60 mg Prolonged-Release Tablet | Rx | Genom Biotech Pvt. Ltd. (India) | 1 |
| Isorgin | 20 mg Tablet | Rx | Cisen Pharmaceutical Co., Ltd. (China) | 1 |
| Isorlife | 60 mg Prolonged-Release Tablet | Rx | Flourish Pharma (India) | 1 |
| Isormed | 30 mg Prolonged-Release Tablet; 60 mg Prolonged-Release Tablet | Rx | Sapphire Lifesciences Pvt. Ltd. (India) | 2 |
| Monobide-10 | 10 mg Tablet | Rx | Brawn Laboratories Limited (India) | 1 |
| Monobide-20 | 20 mg Tablet | Rx | Brawn Laboratories Limited (India) | 1 |
| Monoguard 30 | 30 mg Sustained-Release Tablet | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd. (China) | 1 |
| Montra | 30 mg Sustained-Release Capsule; 60 mg Sustained-Release Capsule | Rx | Inventia Healthcare Limited (India) +1 more | 2 |
| Nitraphil | 30 mg Sustained-Release Tablet | Rx | Fredun Pharmaceuticals Limited (India) | 1 |
| Nitrofix SR | 30 mg Prolonged Release Tablet; 60 mg Prolonged-Release Tablet | Rx | Micro Labs Limited (India) +1 more | 2 |
| Saphorbide-30 | 30 mg Prolonged-Release Tablet | Rx | Sai Parenterals Ltd. (India) | 1 |
| Vasotrate-120 OD | 120 mg Extended-Release Tablet | Rx | Torrent Pharmaceuticals, Ltd. (India) | 1 |
| Vasotrate-60-OD | 60 mg Sustained-Release Tablet | Rx | TORRENT PHARMACEUTICALS LTD. (India) | 1 |
| Zorvien 30 | 30mg Prolonged-Release Tablet | Rx | Azarias Pharmaceutical Laboratories Inc. (Philippines) | 1 |
| No brand (generic) | 30 mg Prolonged Release Tablet; 30 mg Prolonged-Release Tablet; 60 mg Prolonged-Release Tablet | Rx | Lloyd Laboratories, Inc. (Philippines) +2 more | 5 |
Source: FDA Philippines product registry, checked 2026-11-05. Look up any registration number at verification.fda.gov.ph.
Official leaflets
The package insert (PI) and patient leaflet (PIL) filed with FDA Philippines. Doses, side effects and warnings are there, written by the maker and approved by FDA.
- Nitrofix SR: package insert (PI) (DRP-7996)
- Nitrofix SR: package insert (PI) (DRP-7995)
Paying less for isosorbide mononitrate
- Ask for the generic
Prescriptions are written in generic names, and the pharmacist must tell you every brand of that generic and its price. How it works
- Senior or PWD card
20% off plus no VAT on your own medicines, with ID and prescription. What to bring
- No VAT on this one
It is on the FDA VAT-exempt list, so the 12% VAT should not be on your receipt. The list
Questions people ask
Do I need a prescription for isosorbide mononitrate in the Philippines?
FDA Philippines classifies isosorbide mononitrate as a prescription (Rx) medicine. A pharmacist may dispense it only against a valid prescription (Pharmacy Act, RA 10918).
Is there a generic isosorbide mononitrate registered in the Philippines?
FDA Philippines lists 41 registered isosorbide mononitrate products (checked 2026-11-05): 5 sold under the generic name only and 36 under 27 brand names. Ask the pharmacist for the unbranded generic: same ingredient and strength.
How much does isosorbide mononitrate cost in the Philippines?
The DOH Drug Price Reference Index, June 2024 edition, lists isosorbide-5-mononitrate 30 mg modified release capsule at a median of ₱6.05 (range ₱4.90 to ₱7.50). That is what public hospitals pay; drugstore prices are usually higher.
Where can I buy isosorbide mononitrate legally?
From an FDA-licensed drugstore or botika; the licence to operate (LTO) should be displayed in the store. Bring your prescription. Check that the box carries a DR- registration number, and be careful with online sellers that are not licensed pharmacies.
Is isosorbide mononitrate over the counter in the Philippines?
No. FDA Philippines lists all registered isosorbide mononitrate products, such as 30 mg and 60 mg extended-release tablets, as prescription (Rx) drugs.
Can I crush isosorbide mononitrate extended-release tablets?
No. The US label says to swallow them whole without chewing or crushing.
Is isosorbide mononitrate the same as isosorbide dinitrate?
No. They are two medicines with different doses. The US label describes the mononitrate as the main active substance the body makes from the dinitrate. Products sold simply as "isosorbide" 20 to 60 mg, such as Imdur, are the mononitrate.
Can isosorbide mononitrate stop an angina attack?
No. The label says it acts too slowly to end an attack that has already started. It is taken every day to prevent angina.
Data: FDA Philippines registry (checked 2026-11-05), DOH Drug Price Reference Index (June 2024). Sources and method.